BMS
Bristol-Myers Squibb hires new general manager




June 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, Johanna Mercier
Johanna Mercier has been appointed as Bristol-Myers Squibb’s general manager for the UK and Ireland. The appointment of Mercier who …
GSK signs Adaptimmune deal
June 3, 2014Manufacturing and Production, Research and Development, Sales and Marketing AZ, Adaptimmune, BMS, Cancer, GSK, oncology
GlaxoSmithKline has signed a deal to develop and commercialise biotech firm Adaptimmune’s lead clinical cancer programme with T-cell receptors (TCRs), …
Taiho hires head from BMS
May 29, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, taiho, whiten
Japan-based pharma firm Taiho Oncology has appointed Tim Whitten to the position of senior vice president and chief commercial officer. …
BMS signs cancer deal
May 28, 2014Research and Development, Sales and Marketing ASCO, AstraZeneca, BMS, Cancer, Merck, Roche, cytomx, oncology
Bristol-Myers Squibb has partnered with CytomX Therapeutics to discover and develop new immuno-oncology candidates using the latter’s Probody Platform technology. …
BMS and AbbVie get FDA lift
May 21, 2014Research and Development, Sales and Marketing AbbVie, BMS, FDA, elotuzumab, multiple, myeloma
Bristol-Myers Squibb and AbbVie are celebrating after receiving breakthrough designation status from the US regulator for their investigational medicine elotuzumab …
BMS expands Samsung deal
April 29, 2014Manufacturing and Production BMS, Roche, Samsung, UCSF, biologics, incheon
Bristol-Myers Squibb has expanded its biopharmaceutical manufacturing agreement with South Korea’s Samsung BioLogics. Last year, Bristol-Myers Squibb signed a 10-year …
Profits slump at AstraZeneca
April 24, 2014Sales and Marketing AZD9291, AstraZeneca, BMS, Brilinta, Q1
AstraZeneca has continued its poor run of form, with operating profit in the first quarter of 2014 falling 40% on …
BMS hopes for Yervoy sequel with new deal
March 18, 2014Research and Development, Sales and Marketing Avapro, BMS, Plavix, Yervoy, five prime, immune-oncology
Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …
160 jobs in peril at BMS Ireland plant
March 7, 2014Manufacturing and Production, Sales and Marketing BMS, Cruiserath, Dublin, Ireland, swords
Bristol-Myers Squibb will close its Dublin manufacturing facility at Cruiserath in Ireland by the end of 2015 the firm has …
BMS/AZ fat disorder drug gains FDA approval
February 26, 2014Research and Development, Sales and Marketing AstraZeneca, BMS, FDA, hep C, metreleptin, myalept
Bristol-Myers Squibb and partner AstraZeneca have been granted FDA approval for a new drug to treat rare and potentially fatal …
NICE restricts Yervoy use
February 25, 2014Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
BMS revenue drops in 2013
January 27, 2014Sales and Marketing AZ, BMS, Yervoy, diabetes, hep C, q4
Bristol-Myers’ Squibb’s revenue has fallen 7% year-on-year to $16.4 billion during 2013. Turnover rose 6% to $4.4 billion in the …
FDA approves Farxiga
January 10, 2014Sales and Marketing AstraZeneca, BMS, FDA, Forxiga, diabetes
The FDA has approved Farxiga, the diabetes treatment developed by AstraZeneca and Bristol-Myers Squibb as part of their soon-to-be-defunct diabetes …
